Fig. 7: Mass spectrometry validation of protein biomarkers in the validation cohort. Patients with normal cognition (PDNC) were compared to those with mild impairment or dementia (PDMCI_PDD) in the validation cohort. The figure were performed with R (version3.6.2). | npj Parkinson's Disease

Fig. 7: Mass spectrometry validation of protein biomarkers in the validation cohort. Patients with normal cognition (PDNC) were compared to those with mild impairment or dementia (PDMCI_PDD) in the validation cohort. The figure were performed with R (version3.6.2).

From: Machine learning model base on metabolomics and proteomics to predict cognitive impairment in Parkinson’s disease

Fig. 7

Abundance of the protein biomarkers (a) H3C15 and PSAP and (b) NCAM2 and LAMB2. *P < 0.05; P-values from student’s t-test are shown. Lines indicate median and interquartile range. n = 35 (PDNC), 62 (PDMCI_PDD). Receiver operating characteristic curves for the combination of (c) H3C15 and PSAP or (d) all four protein biomarkers on the left, and the classification error matrices on the right. Areas under the operating curves are shown within the curve plots.

Back to article page